Navigation Links
Oral Vaccine May Help People With COPD
Date:4/6/2010

Preliminary results suggest a new option to treat the breathing disease

TUESDAY, April 6 (HealthDay News) -- An experimental vaccine for chronic obstructive pulmonary disease (COPD), a progressive respiratory disease that afflicts millions of people, may reduce flare-ups in those with severe forms of the illness, new research finds.

Unlike regular childhood vaccinations or the flu shot, this vaccine, which is made from the bacteria that causes meningitis in children, does not prevent COPD but rather tames the severity, duration and frequency of flare-ups.

"It's not an ideal study but it is suggestive that using this novel oral vaccine can reduce the number of serious COPD exacerbations," said Dr. Norman H. Edelman, chief medical officer of the American Lung Association. "That's a very significant finding and could be a very, very useful tool in the management of severe COPD."

Dr. Len Horovitz, a pulmonary specialist with Lenox Hill Hospital in New York City, added, "they're modest results but certainly favorable and it would seem to be non-toxic."

COPD, which is usually caused by smoking, is the fourth leading cause of death in the United States and, said Edelman, is "a major, major problem."

Currently available treatments include flu and pneumonia shots to prevent infection, and oxygen and medications to improve quality of life. It's unclear if any of these interventions actually prolong life, Edelman said.

"There's not a lot new under the sun," Horovitz said.

Flare-ups of COPD seem to be caused by the wrong bacteria or the wrong proportion of bacteria in the airways, which results in inflammation.

"This [new study] is capitalizing on the theory that the inflammation responses due to colonization of bacteria is different in COPD," Horovitz explained."

The vaccine studied in the new trial, HI-164OV, is made from inactivated Haemophilus influenzae, the bacteria responsible for meningitis in children. The study authors, from Australia, were hoping that this inactivated bacteria would trigger a beneficial change in bacteria colonization.

The trial was a small one, involving only 38 people, all with severe COPD. The patients were randomly selected to receive either the new HI-164OV oral vaccine or a placebo along with best available treatment.

The study showed encouraging results.

Although overall COPD exacerbations only went down by 16 percent, moderate-to-severe exacerbations (those requiring corticosteroids) were reduced by 63 percent. The average length of an exacerbation declined by 37 percent, while antibiotics prescriptions declined 56 percent. And hospitalizations were reduced by 90 percent.

The findings were published in the April issue of the journal Chest.

Many of the study authors reported ties with Hunter Immunology Ltd., an Australian biopharmaceutical company that makes HI-164OV.

More information

The U.S. National Heart, Lung, and Blood Institute has more on COPD.



SOURCES: Norman H. Edelman, M.D., chief medical officer, American Lung Association, Washington, D.C.; Len Horovitz, M.D., pulmonary specialist, Lenox Hill Hospital, New York City; April 2010, Chest


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Genetic Engineering Raises Hope for Lyme Disease Vaccine
2. Only 1 in 4 Americans Got H1N1 Vaccine
3. Clues Found to How Different Flu Vaccines Work
4. GSK Joins Global Vaccine Alliance to Help Prevent Millions of Children from Contracting Pneumococcal Disease in the Worlds Poorest Countries
5. Miles for Hope’s Moving Towards A Cure(SM) Brain Tumor Walk in Boston Raising Funds for Brain Tumor Vaccine and Massachusetts General Hospital
6. FDA Asks Docs to Suspend Using Glaxo Rotavirus Vaccine
7. GlaxoSmithKline Statement on New Information Relating to Manufacture of Rotarix (Rotavirus Vaccine)
8. Keeping up with the neighbors speeds vaccine use
9. Young Kids to Benefit From Broader Pneumococcal Vaccine
10. The Pediatric Dengue Vaccine Initiative Introduces www.DengueWatch.org - a News hub for Tracking Dengue Fever Epidemics Worldwide
11. 1 in 5 At-Risk U.S. Babies Doesnt Get Hepatitis B Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 According to a ... (Standard Pen Needles, Safety Pen Needles), Needle Length (4mm, ... Hormone), Mode of Purchase (Retail, Non-Retail) - Trends & ... studies the market for the forecast period of 2016 ... 2.81 Billion by 2021 from USD 1.65 Billion in ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
Breaking Medicine Technology: